Stability testing for compounded antidepressant oral liquids
2 Jun 2025 - 30 Sep 2026
People funded by this grant:
Cooper N,
Hoyle D,
Patel R,
Wanandy T,
Williams M
Project Total: $150,000;
This project aims to develop and validate standardised formulas for compounding antidepressant oral liquids in pharmacies, ensuring patients have safe and accessible options for hyperbolic tapering of antidepressant. Specifically, we will:
Develop formulas for the preparation of oral liquids using commercially available antidepressant products and suspending and flavouring agents.
Conduct chemical and physical stability testing to ensure these formulations remain physicochemically stable over time.
Perform microbiological stability testing
to assess the risk of microbial contamination in the prepared products throughout the period studied.
To align with the RELEASE hyperbolic tapering guidelines,15 we will test 11 antidepressants* using oral liquid strengths recommended within these resources. The selected antidepressants include all those listed in the RELEASE tapering plans, with the exception of:
Escitalopram, which already has a commercially available liquid formulation.
Venlafaxine, duloxetine, and desvenlafaxine, which cannot safely be compounded outside of a compounding pharmacy due to their specialised drug release characteristics.
The developed formulas will be tested for their physicochemical and microbiological stability over 60 days, to determine their shelf-life. These formulas will be available to be:
Published in the Australian Pharmaceutical Formulary and Handbook and peer-reviewed scientific journals, making them easily accessible to all pharmacies.17
Disseminated through professional networks, including the Pharmaceutical Society of Australia, to ensure widespread adoption.
This will provide patients with a safe and affordable method for hyperbolic tapering, eliminating the need for imprecise and inefficient at-home methods (e.g., crushing and dispersing commercial tablets) and improving access to appropriate antidepressant formulations.
*Included antidepressants:
Selective Serotonin Re-uptake Inhibitors (SSRIs): Sertraline, fluoxetine, citalopram, paroxetine, fluvoxamine;
Others: Agomelatine, mianserin, mirtazapine, moclobemide, reboxetine, vortioxetine.
Funded by: Wilson Foundation ($150,000); University of Tasmania.
GRANT
ReMInDAR Trial Reducing Medicine Induced Deterioration and Adverse Reactions Trial
1 May 2018 - 31 Mar 2021
People funded by this grant:
Bereznicki L,
Roughead L,
Pratt N,
Parfitt G,
Cousins J
Project Total: $2,847,927; This randomised controlled trial will assess a pharmacist led intervention to reduce medicine induced deterioration and adverse reactions. Medicine induced deterioration encompasses the spectrum of side effects that are frequently not recognised as medication related but are misattributed as geriatric syndromes, frailty or changes due to aging?. The aim of the service is to enable early identification of signs and symptoms of medicine- induced deterioration so that worsening frailty and subsequent adverse events, such as injurious falls, fractures and delirium are prevented. In implementing the service, the pharmacist will use a suite of validated tools to assist in the detection of signs and symptoms of medicine-induced deterioration. The validated tools will encompass assessments to monitor changes in cognition, change in 24-hour movement behavior, including sleep, as well as grip strength. In addition, pharmacists will assess the potential for adverse medicine events via review of the resident care assessment record and through patient or carer reported changes in health since the medicine regimen was changed. The pharmacist service will be compared with usual care. The trial, involving 500 patients will take place in aged-care facilities in South Australia and Tasmania. Evaluation will encompass health program, clinical and economic evaluation. The expected clinical outcome is a reduction in medication-induced deterioration, as measured by change in frailty score. Adverse events will be measured as a secondary outcome. The cost- effectiveness evaluation will assess cost per adverse event avoided. Funded by: Department of Health, Disability and Ageing (Cth) - Pharmacy Trial Program (Tranche 2) ($2,847,927); University of Tasmania.
GRANT
Vitamin D and calcium supplementation amongst residents of aged care facilities in Australia: are guidelines being followed?
1 Jan 2015 - 31 Mar 2016
People funded by this grant:
Williams M,
Curtain C
Project Total: $16,100; Funded by: University of Tasmania - Grant-Research Enhancement (REGS); University of Tasmania ($16,100).